Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 ... Novo Nordisk's once-daily injectable weight loss therapy Saxenda (liraglutide) has been a slow ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.